메뉴 건너뛰기




Volumn 3, Issue 7, 2012, Pages 829-835

Chimerically designed HDAC- and tyrosine kinase inhibitors. A series of erlotinib hybrids as dual-selective inhibitors of EGFR, HER2 and histone deacetylases

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BELINOSTAT; ENTINOSTAT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; ERLOTINIB DERIVATIVE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; MOCETINOSTAT; PANOBINOSTAT; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; VORINOSTAT;

EID: 84863649774     PISSN: 20402503     EISSN: 20402511     Source Type: Journal    
DOI: 10.1039/c2md00317a     Document Type: Article
Times cited : (32)

References (32)
  • 20
  • 31
    • 0002658306 scopus 로고
    • ed. T.-C. Chou and D. C. Rideout, Academic Press, San Diego
    • T. C. Chou, in Synergism and Antagonism in Chemotherapy, ed., T.-C. Chou, and, D. C. Rideout, Academic Press, San Diego, 1991, p. 61
    • (1991) Synergism and Antagonism in Chemotherapy , pp. 61
    • Chou, T.C.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.